PAREXEL Ranked #1 Among Global CROs for Leadership in Phase II/III Clinical Research in Prominent Annual ISR CRO Quality Benchmark Survey

Company recognized for service provider leadership among global

Also named a 2019 CRO Leadership Award Winner

BOSTON–(BUSINESS WIRE)–PAREXEL International Corporation, a leading innovator of global
biopharmaceutical services, today announced it has been ranked #1 among
global Clinical Research Organizations (CROs) for service provider
leadership in Phase II/III clinical research according to a global
survey of pharmaceutical and biotechnology companies by Industry
Standard Research (ISR)
. As a result of the survey, which assessed
60 CROs on 20+ performance metrics, PAREXEL also was named the recipient
of a 2019 CRO Leadership Award from Life Science Leader magazine
for meeting or exceeding customer expectations across six different

ISR’s report, titled “CRO
Quality Benchmarking – Phase II/III Service Providers (11th
,” surveyed 290
biopharmaceutical professionals across North America, Europe and Asia.
In addition to ranking #1 for service provider leadership with 67
percent of respondents recognizing PAREXEL in this category, the company
also received recognition for:

  • Highest customer loyalty score and only large provider to top the list
    for the category
  • Lowest staff turnover among large providers
  • Among the top performers in patient recruitment and study monitoring
  • Highest brand index score based on awareness, familiarity and

“Phase II and III clinical research are critical steps along the drug
development journey and PAREXEL’s focus first and foremost is on quality
execution to expedite the delivery of important new therapies to the
patients who need them,” notes Gadi Saarony, Executive Vice President
and Chief Clinical Research Services Officer, PAREXEL. “We are proud of
our 20,000 employees worldwide whose passion for making a difference in
patients’ lives and commitment to our customers has resulted in this
recognition. We look forward to continuing to build on our strong track
record of advancing new therapies efficiently and effectively.”

PAREXEL received a 2019 CRO Leadership Award from Life Science Leader for
meeting or exceeding customer expectations across six categories
including Capabilities, Compatibility, Expertise, Phase IV, Quality and
Reliability, which are measured based on a subset of report data. This
is the eighth consecutive time PAREXEL has received this award.

Over the past five years, PAREXEL has supported 5,260 Phase II and Phase
III studies in 14 therapeutic areas. For more information on PAREXEL’s
Phase II/III services, visit parexel.com/journey/phase-ii-iii.

About PAREXEL International

PAREXEL International Corporation is a leading innovator of global
biopharmaceutical services. We simplify our clients’ journey of
transforming scientific discoveries into new medical treatments for
patients with high-quality Phase I-IV clinical research, regulatory,
consulting and market access services. PAREXEL helps to develop
innovations and solutions by leveraging its comprehensive therapeutic,
technical and functional expertise, in more than 100 countries around
the world. For more information, visit our website and
follow us on LinkedIn
and Twitter.

PAREXEL is a registered trademark of PAREXEL International Corporation.
All other trademarks are the property of their respective owners.


PAREXEL Contacts:

Wendy Ryan
+1 781-434-5104
Email: [email protected]

McMahon Arrigg, PAN Communications
Tel.: +1 617-502-4300
Email: [email protected]

Read the full article

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.